EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics

Eisuke Adachi iD, Rumi Minami iD, Michinori Shirano, Hideta Nakamura iD, Kazuaki Fukushima iD, Mayumi Imahashi iD, Ryoko Sekiya, Yusuke Yoshino iD, Toshibumi Taniguchi iD, J‐HIV RWD Collaborative Database Team

HIV Medicine · 2025

DOI: 10.1111/hiv.70096 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift HIV Medicine, 2025. Verfasst von Eisuke Adachi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, Pyridones, Rilpivirine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Long‐acting cabotegravir plus rilpivirine (CAB+RPV) offers an alternative to daily oral therapy, but real‐world data in East Asia remain scarce. This study aims to evaluate the impact of CAB+RPV in people with HIV in Japan, focusing on virological outcomes, treatment continuation and inflammatory markers, providing valuable insight into the use of injectable regimens in clinical practice.

Methods

This multicentre retrospective study analysed routinely collected data from eight HIV centres in Japan on people with HIV who initiated CAB+RPV before January 2024. Virological, renal, inflammatory and lipid outcomes were assessed using follow‐up laboratory data obtained through April 2025.

Results

Among 136 participants, over 95% maintained HIV RNA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsPyridonesRilpivirineAdultFemaleHumansMaleMiddle AgedBiomarkersCD4 Lymphocyte CountDrug Therapy, CombinationJapanRetrospective StudiesTreatment OutcomeViral LoadDiketopiperazines

Stichwörter der Autor:innen

HIVantiretroviral therapycabotegravir plus rilpivirinechronic inflammationlong‐acting injectablereal‐world data

Substanzen

Anti-HIV AgentsBiomarkerscabotegravirPyridonesRilpivirineDiketopiperazines

Autor:innen und Institutionen

  • Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Internal Medicine, Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka, Japan.
  • Department of Infectious Diseases, Osaka City General Hospital, Osaka, Japan.
  • Division of Infectious, Respiratory, and Digestive Medicine, First Department of International Medicine, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan.
  • Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan.
  • Department of Infectious Diseases, NHO Nagoya Medical Center, Nagoya, Japan.

ORCID-Profile: Eisuke Adachi, Rumi Minami, Hideta Nakamura, Kazuaki Fukushima, Mayumi Imahashi, Yusuke Yoshino, Toshibumi Taniguchi

Zitieren

APA

Adachi, E., Minami, R., Shirano, M., Nakamura, H., Fukushima, K., Imahashi, M., Sekiya, R., Yoshino, Y., Taniguchi, T., & J‐HIV RWD Collaborative Database Team (2025). Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics. HIV Medicine. https://doi.org/10.1111/hiv.70096

Vancouver

Adachi E, Minami R, Shirano M, Nakamura H, Fukushima K, Imahashi M, et al. Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics. HIV Medicine. 2025. doi:10.1111/hiv.70096

BibTeX
@article{Adachi2025,
  author = {Adachi, Eisuke and Minami, Rumi and Shirano, Michinori and Nakamura, Hideta and Fukushima, Kazuaki and Imahashi, Mayumi and Sekiya, Ryoko and Yoshino, Yusuke and Taniguchi, Toshibumi and J‐HIV RWD Collaborative Database Team, J‐HIV RWD Collaborative Database Team},
  title = {Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics},
  journal = {HIV Medicine},
  year = {2025},
  doi = {10.1111/hiv.70096}
}
Kostenlos starten →